Medical Training Application Service Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
CONCLUSION: The administration of MTAs in patients with intermediate-stage HCC contributes to the prevention of stage progression and prolongs OS.PMID:34518483 | DOI:10.1159/000518612 (Source: Oncology)
Source: Oncology - September 14, 2021 Category: Cancer & Oncology Authors: Shigeo Shimose Hideki Iwamoto Masatoshi Tanaka Takashi Niizeki Tomotake Shirono Akira Kajiwara Yu Noda Naoki Kamachi Shusuke Okamura Masahito Nakano Ryoko Kuromatsu Takumi Kawaguchi Hironori Koga Takuji Torimura Source Type: research

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Conclusion: The administration of MTAs in patients with intermediate-stage HCC contributes to the prevention of stage progression and prolongs OS.Oncology (Source: Oncology)
Source: Oncology - September 8, 2021 Category: Cancer & Oncology Source Type: research

Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
AbstractThe addition of molecular targeted agents (MTAs) to R-CHOP has been one of the main focuses of research in patients with DLBCL. Despite encouraging preliminary results, recent randomized controlled trials (RCT) have not shown a definitive benefit over standard R-CHOP. Here we conducted a systematic review and meta-analysis to investigate the impact of this strategy. A systematic literature review was conducted to identify RCT that evaluated the addition of MTA to R-CHOP-based regimen versus R-CHOP alone in previously untreated DLBCL patients. Fixed and random effects models were used to estimate pooled hazard ratio...
Source: Annals of Hematology - August 10, 2021 Category: Hematology Source Type: research

Cancers, Vol. 13, Pages 3958: Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
The objective response rate (ORR) at six weeks after the start of treatment, changes in α-fetoprotein (AFP) and des-γ-carboxyprothrombin, incidence of adverse events (AEs), and changes in albumin-bilirubin (ALBI) score and serum ammonia level, were evaluated. Among 40 patients, 24 had histories of prior molecular targeted agents (MTAs). The ORR was 22.5% based on mRECIST. Multivariate analysis showed that an AFP ratio &lt;1.0 at three weeks (odds ratio 39.2, 95% confidence interval CI 2.37–649.0, p = 0.0103) was the only significant factor for predicting early response. There was no significant difference in th...
Source: Cancers - August 5, 2021 Category: Cancer & Oncology Authors: Yuwa Ando Tomokazu Kawaoka Masanari Kosaka Yuki Shirane Yusuke Johira Ryoichi Miura Serami Murakami Shigeki Yano Kei Amioka Kensuke Naruto Yumi Kosaka Shinsuke Uchikawa Kenichiro Kodama Hatsue Fujino Takashi Nakahara Atsushi Ono Eisuke Murakami Masami Yam Tags: Article Source Type: research

Quantitative genetics: pan-genomes, SVs, and k-mers for GWAS
Trends Genet. 2021 Jun 25:S0168-9525(21)00138-4. doi: 10.1016/j.tig.2021.05.006. Online ahead of print.ABSTRACTFor identification of marker-trait associations (MTAs) for complex traits in animals and plants, thousands of genome-wide association studies (GWAS) were conducted during the past two decades. This involved regular improvement in methodology. Initially, a reference genome and SNPs were used; more recently pan-genomes and the markers structural variations (SVs)/k-mers are also being used.PMID:34183185 | DOI:10.1016/j.tig.2021.05.006 (Source: Trends in Genetics : TIG)
Source: Trends in Genetics : TIG - June 29, 2021 Category: Genetics & Stem Cells Authors: Pushpendra K Gupta Source Type: research

Polyphenol oxidase genes as integral part of the evolutionary history of domesticated tetraploid wheat
Genomics. 2021 Jun 25:S0888-7543(21)00247-0. doi: 10.1016/j.ygeno.2021.06.030. Online ahead of print.ABSTRACTStudying and understanding the genetic basis of polyphenol oxidases (PPO)-related traits plays a crucial role in genetic improvement of crops. A tetraploid wheat collection (T. turgidum ssp., TWC) was analyzed using the 90 K wheat SNP iSelect assay and phenotyped for PPO activity. A total of 21,347 polymorphic SNPs were used to perform genome-wide association analysis (GWA) in TWC and durum wheat sub-groups, detecting 23 and 85 marker-trait associations (MTA). In addition, candidate genes responsible for PPO activit...
Source: Genomics - June 28, 2021 Category: Genetics & Stem Cells Authors: Francesca Taranto Giacomo Mangini Monica Marilena Miazzi Piergiorgio Stevanato Pasquale De Vita Source Type: research

A comprehensive assessment of a new series of 5',6'-difluorobenzotriazole-acrylonitrile derivatives as microtubule targeting agents (MTAs)
Eur J Med Chem. 2021 Jun 1;222:113590. doi: 10.1016/j.ejmech.2021.113590. Online ahead of print.ABSTRACTMicrotubules (MTs) are the principal target for drugs acting against mitosis. These compounds, called microtubule targeting agents (MTAs), cause a mitotic arrest during G2/M phase, subsequently inducing cell apoptosis. MTAs could be classified in two groups: microtubule stabilising agents (MSAs) and microtubule destabilising agents (MDAs). In this paper we present a new series of (E) (Z)-2-(5,6-difluoro-(1H)2H-benzo[d] [1,2,3]triazol-1(2)-yl)-3-(R)acrylonitrile (9a-j, 10e, 11a,b) and (E)-2-(1H-benzo[d] [1,2,3]triazol-1-y...
Source: European Journal of Medicinal Chemistry - June 17, 2021 Category: Chemistry Authors: Federico Riu Luca Sanna Roberta Ibba Sandra Piras Valentina Bordoni M Andrea Scorciapino Michele Lai Simona Sestito Luigi Bagella Antonio Carta Source Type: research

The X-ray structure of tubulysin analogue TGL in complex with tubulin and three possible routes for the development of next-generation tubulysin analogues
Biochem Biophys Res Commun. 2021 Jun 2;565:29-35. doi: 10.1016/j.bbrc.2021.05.086. Online ahead of print.ABSTRACTMicrotubule-targeting agents (MTAs) are the most commonly used anti-cancer drugs. At least fourteen microtubule inhibitors and ten antibody drug conjugates (ADCs) linking MTAs are approved by FDA for clinical use in cancer therapy. In current research, we determined the crystal structure of tubulysin analogue TGL in complex with tubulin at a high resolution (2.65 Å). In addition, we summarized all of the previously published high-resolution crystal structures of ligands in the vinca site to provide structural i...
Source: Biochemical and Biophysical Research communications - June 5, 2021 Category: Biochemistry Authors: Wenting Li Lun Tan Zhixiong Zhang Qiuqi Xia Dongsheng Lei Yuyan Li Ting Zhang Shaoxue Zeng Xiutian Sima Yanyan Wang Source Type: research

Cancers, Vol. 13, Pages 2783: Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
ooberry Extracellular vesicles play a central role in intercellular communication and contribute to cancer progression, including the epithelial-to-mesenchymal transition (EMT). Microtubule targeting agents (MTAs) including eribulin and paclitaxel continue to provide significant value in cancer therapy and their abilities to inhibit oncogenic signaling pathways, including eribulin’s capacity to reverse EMT are being revealed. Because microtubules are involved in the intracellular trafficking required for the formation and cargo loading of small extracellular vesicles (sEVs), we investigated whether MTA-mediated disru...
Source: Cancers - June 3, 2021 Category: Cancer & Oncology Authors: Petra J. Pederson Huiyun Liang Daria Filonov Susan L. Mooberry Tags: Article Source Type: research